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Abstract
Background: The relevance of prostate-specific membrane antigen (PSMA) targeting in the clinical management
of prostate cancer (PCa) is continually increasing, entailing the development of PSMA-targeted molecular probes.
Recently, a first PSMA-targeted theranostic concept has been successfully implemented by [68Ga/177Lu]PSMA-I&T.
To further exploit the excellent PSMA-targeting characteristics and in vivo performance of the PSMA-I&T platform,
[111In]PSMA-I&T was evaluated as a complementary probe for radioguided surgery and SPECT imaging.
Findings: Compared to [68Ga/177Lu]PSMA-I&T, [111In]PSMA-I&T showed unchangedly high PSMA-affinity and
enhanced internalization into PSMA-expressing LNCaP PCa cells. Biodistribution studies in LNCaP xenograft-bearing
mice (1 h p.i.) revealed slightly reduced background accumulation of [111In]PSMA-I&T compared to [177Lu]PSMA-I&T
and identical tumor uptake of both compounds, leading to increased tumor/background ratios for [111In]PSMA-
I&T. An exemplary patient with metastatic PCa underwent preoperative [68Ga]HBED-CC-PSMA PET/CT (1 h p.i.) and
[111In]PSMA-I&T SPECT/CT (4 h p.i.), followed by prostatectomy and radioguided extended pelvic lymphadenectomy
(24 h p.i.). In [111In]PSMA-I&T SPECT/CT, the previously identified PCa lesions ([68Ga]HBED-CC-PSMA PET/CT) showed
high tracer accumulation and were also detectable using planar scintigraphy. The intraoperative use of a hand-held
gamma probe allowed detection and resection of all [111In]PSMA-I&T-accumulating lesions. The presence of PSMA-
positive tumor tissue in the resected specimens was confirmed histopathologically and via [111In]PSMA-I&T
autoradiography.
Conclusions: [111In]PSMA-I&T shows efficient PSMA targeting in vitro and in vivo, combined with low background
accumulation. In an exemplary PCa patient, [111In]PSMA-I&T was successfully applied for preoperative SPECT/CT
visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [111In]PSMA-I&T as
a complementary tool to [68Ga/177Lu]PSMA-I&T in the clinical management of prostate cancer.
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Findings
Modern clinical management of prostate cancer increas-
ingly relies on exploiting the prostate-specific membrane
antigen (PSMA) as a molecular target both for imaging
and for treatment of prostate cancer (PCa). PSMA is
abundantly expressed on the surface of prostate cancer
cells and within the neovasculature of other solid tu-
mors, with limited expression in most normal tissues,
establishing the basis for selective targeting of PCa le-
sions with PSMA-targeted agents. Among the rapidly in-
creasing number of high-affinity PSMA ligands, ranging
from intact antibodies to low-molecular-weight com-
pounds, urea-based inhibitors have been most exten-
sively leveraged, with expanding clinical use [1].
Recently, a successful theranostic concept has been re-
alized by the development of [68Ga/177Lu]PSMA-I&T
[2]. Compared to first DOTA-conjugated EuK(=Glu-
urea-Lys)-based inhibitors [3], the DOTAGA-conjugate
PSMA-I&T has been optimized with respect to PSMA
affinity and in vivo stability [2, 4]. First patient studies
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have demonstrated excellent PSMA targeting for
[68Ga/177Lu]PSMA-I&T, permitting high-contrast PET
imaging of metastatic PCa with [68Ga]PSMA-I&T and,
based on suitable uptake and retention characteristics,
efficient treatment with its therapeutic analog
[177Lu]PSMA-I&T [5, 6].
The success and ease of implementation of this thera-
nostic approach, relies, among other factors, on the
ability of DOTAGA to form stable complexes with a
broad variety of radiometals [7] and on the negligible
influence of radiometal exchange on the PSMA affinity
of [*M3+]PSMA-I&T (Table 1) [2]. In the present inves-
tigation, these characteristics were exploited to meet
the clinical need for a corresponding gamma-emitting
probe, which on the one hand allows for the intraoper-
ative detection and identification of PSMA-positive tis-
sues during surgery in patients with early recurrent or
primary advanced PCa and on the other hand may add-
itionally be employed for (preoperative) SPECT imaging
(Fig. 1). Given the suitable radionuclide characteristics
of 111In (t½ = 2.8 d, E(γ) = 173, 245 keV) for the
intended applications, PSMA-I&T was labeled with
111In using a standard protocol and was evaluated pre-
clinically and in a first patient.
As anticipated, [natIn]PSMA-I&T shows unchangedly
high PSMA affinity in a competitive binding assay (IC50),
which equals that of its natLu-counterpart. Unexpectedly,
however, internalization efficiency of [111In]PSMA-I&T
into LNCaP prostate cancer cells was found to be mark-
edly enhanced compared to [177Lu]PSMA-I&T (Table 1).
In the case of [68Ga]- and [177Lu]PSMA-I&T, the in-
creased internalization of [177Lu]PSMA-I&T, which cor-
relates with its improved PSMA affinity compared to
[68Ga]PSMA-I&T, was reflected in increased tracer uptake
in PSMA-positive tissues in vivo [2]. For [111In]PSMA-
I&T, however, the observed increase in PSMA-specific
Table 1 PSMA affinities, internalization, and lipophilicity of
In-, Ga-, and Lu-PSMA-I&T




In-PSMA-I&T 7.5 ± 1.5 104 ± 7 −4.5
Ga-PSMA-I&T 9.4 ± 2.9 59 ± 2 −4.3
Lu-PSMA-I&T 7.9 ± 2.4 76 ± 2 −4.1
PSMA affinities were determined in a competitive binding assay using LNCaP
prostate cancer cells and (125I-BA)KuE as radioligand [2]. Data represent means
± SD of n ≥ 3 separate determinations
PSMA-specific ligand internalization was determined by incubation of LNCaP
cells (37 °C, 60 min) with the respective radioligands (0.2 nM) in the absence
(total internalization) and presence (non-specific internalization) of 10 μM
PMPA. Data were corrected for non-specific internalization and normalized to
the specific internalization observed for the reference compound (125I-BA)KuE
in a parallel experiment [2]. Data are means ± SD (n = 3)
Lipophilicities (from n-octanol/PBS partition coefficients POW) were determined
using a shake-flask method; values are means from n = 6 determinations
Fig. 1 Schematic representation of the PSMA-I&T-based theranostic concept for the clinical management of PCa
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cellular uptake compared to [177Lu]PSMA-I&T in vitro has
no detectable influence on PSMA targeting in vivo. In-
stead, [111In]PSMA-I&T and [177Lu]PSMA-I&T show
nearly identical uptake in PSMA-positive LNCaP tumor
xenografts at 1 h p.i. (Fig. 2), in accordance with the identi-
cal PSMA affinity of both compounds.
Besides high tumor uptake, [111In]PSMA-I&T also
shows significant accumulation in tissues with endogen-
ous PSMA expression, i.e., lung and in particular kidney
and spleen (Fig. 1). For the latter two organs, the sub-
stantially increased [111In]PSMA-I&T uptake is not the
result of altered targeting characteristics of the tracer
compared to [177Lu]PSMA-I&T, but is rather caused by
the use of alternative mouse strains for the comparative
evaluation of both compounds (CB17 SCID mice for
[111In]PSMA-I&T vs CD1 nu/nu mice for [177Lu]PSMA-
I&T). Particularly high tracer uptake in spleen and kid-
ney in CB17 SCID mice has been consistently observed
in the evaluation of a variety of PSMA-targeted radio-
pharmaceuticals in our lab and is mouse-strain specific.
In contrast, the accelerated blood clearance and re-
duced background accumulation of [111In]PSMA-I&T,
especially in liver and intestines, are tracer specific. Due
to its reduced lipophilicity compared to [68Ga]PSMA-
I&T and [177Lu]PSMA-I&T (see Table 1), hepatobiliary
excretion is further reduced in favor of almost exclusive
renal excretion. Consequently, [111In]PSMA-I&T shows
improved tumor(t)-to-background ratios compared to
[177Lu]PSMA-I&T at 1 h p.i., i.e., t/blood-, t/liver-, t/in-
testines-, and t/muscle-ratios of 34 ± 8, 32 ± 6, 53 ± 8,
and 43 ± 6, respectively, versus 18 ± 9, 7 ± 3, 12 ± 3, and
14 ± 9 for [177Lu]PSMA-I&T.
Based on these findings, suggesting nearly identical if
not slightly improved in vivo PSMA targeting and excre-
tion characteristics for [111In]PSMA-I&T in comparison
to [68Ga]PSMA-I&T and [177Lu]PSMA-I&T, an exem-
plary patient study was carried out to establish the po-
tential of [111In]PSMA-I&T as an intraoperative probe
for radioguided surgery and to investigate its suitability
as a SPECT-imaging agent. The patient (51 years old),
presenting with histologically confirmed metastasized
prostate cancer (Gleason score 9, initial PSA 63 ng/ml),
initially underwent [68Ga]HBED-CC PSMA PET/CT for
pre-therapeutic staging as previously described [8, 9].
Maximum intensity projection (MIP) showed intense
tracer uptake in the primary tumor (Fig. 3a, solid arrow)
as well as in multiple pelvic and retroperitoneal lymph
node metastases (Fig. 3a, dotted arrows). The patient
Fig. 2 Comparative biodistribution of [111In]- and [177Lu]PSMA-I&T in LNCaP tumor-bearing mice 1 h p.i. Biodistribution studies were carried out
using LNCaP xenograft-bearing CB17 SCID ([111In]PSMA-I&T) or CD-1 nu/nu ([177Lu]PSMA-I&T) mice. Animals were injected intravenously with
1.4 MBq (0.2 nmol) of the respective PSMA-I&T analog. Data are represented as % injected dose per gram tissue (%iD/g) and are means ± SD
(groups of n = 5). Animal experiments were conducted in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval
no. 55.2-1-54-2532-71-13)
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was scheduled for radical prostatectomy facilitated by
radioguided surgery to potentially enhance complete re-
section of lymph node metastases.
One day prior to surgery, the patient was injected
with 155 MBq [111In]PSMA-I&T, and preoperative pla-
nar scintigraphy as well as SPECT/CT were performed
at 4 h p.i. (Fig. 3b, e, h). Radical prostatectomy as well
as radioguided lymphadenectomy using a hand-held
gamma probe with visual and acoustic feedback (Crystal
Probe CXS-SG603; Crystal Photonics, Berlin, Germany)
were performed 24 h after injection of [111In]PSMA-I&T.
The presence of PSMA-positive tumor tissue in the
resected specimens was confirmed histopathologically and
via [111In]PSMA-I&T autoradiography (Fig. 3i, j).
Ventral and dorsal views of whole body planar scintig-
raphy (Fig. 3b) show intense [111In]PSMA-I&T uptake in
the primary tumor (solid arrows) as well as in pelvic and
retroperitoneal lymph node metastases (dotted arrows).
Axial [111In]PSMA-I&T SPECT/CT images confirm the
intense tracer accumulation, both in the primary tumor
(Fig. 3e) and in a representative morphologically not en-
larged lymph node (Fig. 3h) and are consistent with
[68Ga]HBED-CC PSMA PET/CT findings (Fig. 3d, g).
During subsequent prostatectomy and salvage lymphad-
enectomy, the intraoperative use of a gamma probe
allowed the detection and quantitative resection of all
lymph nodes with [111In]PSMA-I&T accumulation. All
resected lesions showing tracer uptake were histopatho-
logically confirmed to be metastatic PCa deposits.
Within the prostate, ex vivo autoradiography 4 h after
surgery showed moderate to intense [111In]PSMA-I&T
uptake in several intraprostatic tumor foci (I) correlating
well with a H&E stained slide from histopathology (J),
demonstrating the sensitive detection of PSMA-
expressing tumor cells by [111In]PSMA-I&T.
Based on these initial promising results, the concept of
radioguided lymphadenectomy in early recurrent prostate






Fig. 3 Preoperative imaging using [68Ga]HBED-CC PSMA PET/CT and [111In]PSMA-I&T SPECT/CT and planar scintigraphy. The human study was
approved by the institutional review boards of the participating medical institutions, and the patient provided signed informed consent. a
[68Ga]HBED-CC PSMA PET/CT (MIP) 1 h p.i. b planar scintigraphy (ventral and dorsal view) 4 h p.i. of 155 MBq [111In]PSMA-I&T. d, g Axial
[68Ga]HBED-CC PSMA PET/CT images of the primary tumor in the prostate (d) and a representative lymph node (g). c, f Corresponding CT
images, and e, h Corresponding axial [111In]PSMA-I&T SPECT/CT images of the primary tumor in the prostate (e) and a representative lymph node
(h). i, j H&E staining and 111In-autoradiography of cryosections from resected prostate tissue
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targeted intraoperative probe has recently been further pur-
sued [10, 11]. In a small cohort of patients, [111In]PSMA-
I&T radioguided surgery was shown to represent a valuable
technique for the intraoperative detection of small subcen-
timeter metastatic lymph nodes and atypically located
lesions.
Additionally, [111In]PSMA-I&T showed promising in
vivo characteristics as a PSMA-targeted SPECT imaging
probe, including suitable whole-body clearance, predom-
inant renal excretion, and efficient accumulation in
PSMA-expressing tissues. Of course, in a direct
comparison, [68Ga]HBED-CC PSMA PET/CT appears as
the clearly superior imaging modality compared to
[111In]PSMA-I&T SPECT/CT. However, this compari-
son is strongly biased in favor of [68Ga]HBED-CC PSMA
PET/CT due to the inherent instrumental differences
between PET and SPECT with respect to sensitivity and
resolution. Furthermore, the comparably high gamma
energy of 111In further challenges spatial resolution of
[111In]PSMA-I&T SPECT/CT.
However, the present preclinical and first clinical
data underline the suitability of PSMA-I&T as a versa-
tile labeling platform for a variety of PSMA-targeted
applications in nuclear oncology and urology, ranging
from PET and SPECT to endoradiotherapy and radio-
guided surgery, encouraging the ongoing further in-
vestigation of [68Ga]PSMA-I&T, [177Lu]PSMA-I&T,
and [111In]PSMA-I&T as valuable tools for their re-
spective dedicated application.
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